266. Familial mediterranean fever
27 clinical trials,   23 drugs   (DrugBank: 6 drugs),   14 drug target genes,   57 drug target pathways

Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000032557
2018/09/0130/05/2018An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intoleranceAn open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance - An open-label continuation trial of tocilizumab for familial Mediterranean fever familial Mediterranean feverTocilizumabDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical SciencesNULLComplete: follow-up continuing12years-oldNot applicableMale and Female24Not selectedJapan
2JPRN-UMIN000028010
2018/03/0107/07/2017Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean feverRandomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever - Clinical trial of Tocilizumab for colchicine-resistant familial Mediterranean fever familial Mediterranean feverTocilizumab
Placebo
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical SciencesNULLComplete: follow-up complete12years-oldNot applicableMale and Female24Not selectedJapan
3NCT03210610
(ClinicalTrials.gov)
October 19, 201729/6/2017Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) PatientsMeasurement of Colchicine Levels in the Serum of FMF PatientsFMF;Colchicine Resistance;Colchicine ToxicityDiagnostic Test: colchicine level measurementSheba Medical CenterNULLUnknown status18 YearsN/AAll80Israel
4NCT02175589
(ClinicalTrials.gov)
June 201424/6/2014Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene MutationControlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene MutationFamilial Mediterranean FeverOther: Colchicine CessationRambam Health Care CampusSchneider Children's HospitalEnrolling by invitation2 Years18 YearsBoth80Phase 2Israel
5NCT02021084
(ClinicalTrials.gov)
December 201329/10/2013The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.Familial Mediterranean Fever (FMF )Dietary Supplement: probiotic;Dietary Supplement: PlaceboRambam Health Care CampusNULLWithdrawn5 Years18 YearsBoth0N/ANULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01705756
(ClinicalTrials.gov)
November 201227/9/2012Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean FeverA Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean FeverFamilial Mediterranean FeverDrug: KineretSheba Medical CenterNULLCompleted18 Years65 YearsAll25Phase 3Israel
7NCT02602028
(ClinicalTrials.gov)
April 20115/11/2015The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMFThe Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized TrialFamilial Mediterranean FeverDrug: colchicineGulhane Military Medical AcademyNULLCompleted5 Years16 YearsBoth79Phase 4Turkey
8NCT01148797
(ClinicalTrials.gov)
December 201021/6/2010Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean FeverColchicine Resistant/Intolerant Familial Mediterranean FeverDrug: CanakinumabNovartis PharmaceuticalsNULLCompleted4 Years20 YearsBoth15Phase 2Israel
9NCT01075906
(ClinicalTrials.gov)
August 201024/2/2010Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) PatientsAn Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMFFamilial Mediterranean FeverDrug: colchicine sprinkle capsulesMutual Pharmaceutical Company, Inc.NULLCompleted2 Years65 YearsBoth75Phase 1United States;Armenia;Israel;Turkey
10NCT01088880
(ClinicalTrials.gov)
April 201016/3/2010Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean FeverAn Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean FeverFamilial Mediterranean FeverDrug: CanakinumabNovartis PharmaceuticalsNULLCompleted12 Years75 YearsBoth10Phase 2Turkey
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2015-003527-57-Outside-EU/EEA
(EUCTR)
14/04/2016Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean FeverAn Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever Familial Mediterranean Fever
MedDRA version: 19.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Ilaris
Product Name: canakinumab
Product Code: ACZ885
INN or Proposed INN: CANAKINUMAB
Novartis PharmaceuticalsNULLNAFemale: yes
Male: yes
9Turkey
12EUCTR2015-003522-13-Outside-EU/EEA
(EUCTR)
14/04/2016Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever Colchicine Resistant/Intolerant Familial Mediterranean Fever
MedDRA version: 19.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Ilaris
Product Name: canakinumab
Product Code: ACZ885
INN or Proposed INN: CANAKINUMAB
Novartis PharmaceuticalsNULLNAFemale: yes
Male: yes
15Phase 2Israel